Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)
- First Posted Date
- 2017-10-19
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 17
- Registration Number
- NCT03314922
- Locations
- 🇯🇵
Cancer Institute Hospital of Jfcr, Koto-ku, Japan
🇯🇵National Cancer Center Hospital, Tokyo, Japan
🇯🇵Nagoya City University Hospital, Nagoya, Japan
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
- First Posted Date
- 2017-10-19
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 149
- Registration Number
- NCT03314935
- Locations
- 🇺🇸
Northwest Georgia Oncology Centers, Marietta, Georgia, United States
🇺🇸USA Mitchell Cancer Center, Mobile, Alabama, United States
🇺🇸University of Alabama, Birmingham, Alabama, United States
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
- Conditions
- Interventions
- First Posted Date
- 2017-08-24
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 129
- Registration Number
- NCT03260894
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇨🇦Sunnybrook Health Sciences, Odette Cancer Centre, Toronto, Ontario, Canada
A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2020-11-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 70
- Registration Number
- NCT03257644
- Locations
- 🇺🇸
Acevedo Clinical Research, Miami, Florida, United States
🇺🇸Rm Medical Research Inc, Miami, Florida, United States
🇺🇸Floridian Research Institute Llc, Miami, Florida, United States
A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)
- First Posted Date
- 2017-08-01
- Last Posted Date
- 2020-05-29
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 44
- Registration Number
- NCT03235570
- Locations
- 🇯🇵
Chiba Cancer Center, Chiba, Japan
🇯🇵Osaka International Cancer Institute, Osaka, Japan
🇯🇵Saitama Cancer Center, Saitama, Japan
A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor
- First Posted Date
- 2017-08-01
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 162
- Registration Number
- NCT03235544
- Locations
- 🇩🇪
Justus-Liebig University, Giessen, Germany
🇮🇹A.O.U. Di Modena - Policlinico, Modena, Italy
🇵🇱University Clinical Center, Gdansk, Poland
An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
- Conditions
- First Posted Date
- 2017-05-10
- Last Posted Date
- 2022-06-07
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT03147742
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸Rutgers Cancer Institute, New Brunswick, New Jersey, United States
🇺🇸Texas Oncology, Dallas, Texas, United States
A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
- First Posted Date
- 2017-05-09
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 110
- Registration Number
- NCT03144674
- Locations
- 🇺🇸
Arizona Oncology Associates, Tempe, Arizona, United States
🇺🇸Sansum Clinic, Santa Barbara, California, United States
🇺🇸UCLA Healthcare Hematology-Oncology, Santa Monica, California, United States
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
- Conditions
- Interventions
- First Posted Date
- 2017-05-09
- Last Posted Date
- 2020-07-15
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 25
- Registration Number
- NCT03144661
- Locations
- 🇧🇪
University Hospital (UZ) Leuven, Leuven, Belgium
🇧🇪Institut Jules Bordet, Brussels, Belgium
🇧🇪Cliniques Universitaires Saint-Luc, Brussels, Belgium
A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2017-05-09
- Last Posted Date
- 2022-06-16
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 23
- Registration Number
- NCT03144687
- Locations
- 🇺🇸
Texas Oncology - Tyler, Tyler, Texas, United States
🇦🇹Paracelsus Medical University Salzburg, Salzburg, Austria
🇺🇸University of Michigan Cancer Center, Ann Arbor, Michigan, United States